Education
About Us
Working with TipRanks
Follow Us
Magle Chemoswed Holding AB (SE:MAGLE)
:MAGLE
MAGLE Stock Chart & Stats
kr17.20
-kr1.20(-3.66%)
At close: 4:00 PM EST
kr17.20
-kr1.20(-3.66%)
Day’s Range― - ―
52-Week Rangekr10.50 - kr35.20
Previous CloseN/A
Volume1.20K
Average Volume (3M)1.06K
Market Cap
kr225.08M
Enterprise Valuekr555.51M
Total Cash (Recent Filing)kr11.80M
Total Debt (Recent Filing)kr338.10M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Feb 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding20,649,378
10 Day Avg. Volume1,291
30 Day Avg. Volume1,058
Financial Highlights & Ratios
PEG Ratio-2.10
Price to Book (P/B)0.79
Price to Sales (P/S)1.88
P/FCF Ratio-15.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginA 93.45% TTM gross margin indicates structural cost advantage in formulation and manufacturing services. High gross margins provide durable cushion to absorb SG&A and R&D, enabling reinvestment in technology and capacity that supports long-term competitiveness and pricing flexibility.
Solid Equity BaseAn equity ratio above 50% signals a conservative capital structure and asset backing, providing resilience through cycles. This solid equity base supports investment in capacity or partnerships without immediate refinancing pressure, aiding multi‑quarter strategic execution and creditor confidence.
Contract Manufacturing And PartnershipsA business model centered on contract manufacturing and partnerships creates diversified, repeatable revenue streams and long-term client relationships. This B2B focus yields predictable project pipelines, cross‑selling of development-to-scale services, and alignment with pharma outsourcing trends.
Bears Say
Negative Operating Cash FlowPersistent negative operating cash flow undermines internal funding for capex, R&D, and working capital. Over multiple quarters this forces reliance on external financing, increases execution risk for scale-up projects, and can limit the firm's ability to capitalize on new partnership opportunities.
Negative Profitability MarginsNegative net and EBIT margins indicate the company is not yet converting strong gross profit into operating profitability. Structural cost or SG&A pressures, or underutilized capacity, must be addressed to achieve sustainable earnings, or profitability will remain a long‑term constraint.
Volatile Cash GenerationExtremely volatile free cash flow growth signals inconsistent conversion of earnings to cash and episodic receipt timing. This volatility complicates multi‑period planning, raises refinancing and liquidity risk, and weakens the firm's ability to fund consistent investment or withstand adverse shocks.
Magle Chemoswed Holding AB News
MAGLE FAQ
What was Magle Chemoswed Holding AB’s price range in the past 12 months?
Magle Chemoswed Holding AB lowest stock price was kr10.50 and its highest was kr35.20 in the past 12 months.
What is Magle Chemoswed Holding AB’s market cap?
Magle Chemoswed Holding AB’s market cap is kr225.08M.
When is Magle Chemoswed Holding AB’s upcoming earnings report date?
Magle Chemoswed Holding AB’s upcoming earnings report date is Feb 27, 2026 which is in 9 days.
How were Magle Chemoswed Holding AB’s earnings last quarter?
Magle Chemoswed Holding AB released its earnings results on Oct 31, 2025. The company reported kr0.152 earnings per share for the quarter, missing the consensus estimate of kr0.2 by -kr0.048.
Is Magle Chemoswed Holding AB overvalued?
According to Wall Street analysts Magle Chemoswed Holding AB’s price is currently Overvalued.
Does Magle Chemoswed Holding AB pay dividends?
Magle Chemoswed Holding AB pays a Notavailable dividend of kr0.35 which represents an annual dividend yield of N/A. See more information on Magle Chemoswed Holding AB dividends here
What is Magle Chemoswed Holding AB’s EPS estimate?
Magle Chemoswed Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Magle Chemoswed Holding AB have?
Magle Chemoswed Holding AB has 20,649,378 shares outstanding.
What happened to Magle Chemoswed Holding AB’s price movement after its last earnings report?
Magle Chemoswed Holding AB reported an EPS of kr0.152 in its last earnings report, missing expectations of kr0.2. Following the earnings report the stock price went down -6.863%.
Which hedge fund is a major shareholder of Magle Chemoswed Holding AB?
Currently, no hedge funds are holding shares in SE:MAGLE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Magle Chemoswed Holding AB
Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacturing in the areas of pharmaceutical chemistry and pharmaceutical technology in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); and research, development, and production of products in the areas of wound care and diagnostics with a focus on products based on degradable starch microspheres. Its APIs include Warfarin sodium products that are used as anticoagulants for multiple indications; Melperone hydrochloride, which is an antipsychotic agent; Isradipine, a calcium channel blocker used to treat hypertension; Amantadine sulfate that is used in the treatment of central nervous system disorders; and Benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers medical devices for applications in the areas of advanced wound care, surgical and diagnostics, and drug delivery comprising EmboCept S, a microsphere based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company's unique microsphere technology; SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures; and EmboCept M, a device for use in the treatment of benign prostatic hyperplasia. It serves companies in the pharmaceutical and medical device industry on a contract basis. The company was founded in 1944 and is headquartered in Malmö, Sweden. Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.
Technical Analysis
Xbrane Biopharma AB
―
Intervacc AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Corline Biomedical AB
―